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Carbachol Regulation of AKT in LNCaP Prostate Cancer Cells
Luke Fletcher and John Michael Schmitt
Biology, George Fox University, Newberg, OR
Abstract
Hormones and agonists that enhance cell survival through binding specific G ProteinCoupled Receptors (GPCRs) are of particular interest in cancer cell survival. LNCaP cells
have been shown to express muscarinic cholinergic receptors that are responsive to the
agonist, carbachol. In addition, LNCaP cells specifically express the M3-subtype of
GPCR’s that may couple carbachol to Gq, increases in intracellular calcium, and
activation of the intracelluar Ca2+/calmodulin-dependent protein kinases (CaM Ks). The
CaM Kinase family of proteins includes CaM KII, CaM Kinase Kinase (CaM KK) and its
substrates CaM KIV, CaM KI and the protein kinase AKT. AKT is an anti-apoptotic enzyme
that phosphorylates BAD and inhibits caspase activation. Our goals were to examine the
mechanism of carbachol activation of AKT in LNCaP prostate cancer cells and evaluate
whether CaM Ks may be mediating carbachol’s activation of AKT and cell survival in
LNCaP cells. The results suggest that AKT phosphorylation was increased in response to
a five-minute stimulation with 10µM carbachol in LNCaP cells which was blocked by the
CaM K family inhibitor, KN-93 suggesting the involvement of the CaM Kinase proteins in
the pathway. In contrast, there was no inhibition by the MEK inhibitor, U0126
suggesting that AKT is activated independently of MEK and ERK. Interestingly, the CaM
KK inhibitor, STO-609 potently inhibited cabachol’s activation of AKT. Furthermore, our
results indicate that carbachol treatment of LNCaP cells promoted cell survival through
CaM Ks. Carbachol’s survival effects also appear to be operating through the M3subtype of GPCRs, CaM KK, and its phosphorylation of AKT.

